What development phase is FLUMEXADOL in?

FLUMEXADOL is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

FLUMEXADOL

FDA-approved withdrawn Small molecule Quality 6/100

FLUMEXADOL is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a stable revenue stream. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	FLUMEXADOL
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FLUMEXADOL CI brief — competitive landscape report
FLUMEXADOL updates RSS · CI watch RSS